Quit Smoking With Lumme

Lack of an effective quit program is a problem faced by 28 million smokers in the US today. Our experts have worked with smokers over the past 15 years, and have come to realize that a personalized program offering just-in-time intervention is key to making the quit attempt successful.


Our Services

Smokers

Keep track of your progress and receive personalized strategies and tips to handle cravings

Wellness Programs

Spend less on employee insurance premiums by helping them quit smoking

Therapist

Keep track of your patient’s progress in real time and help them towards a smoke-free life

Pharma Companies

Improve quit rates by combining our technology with nicotine withdrawal medications



How it works?

The technology developed at Lumme continuously analyzes sensor data from a wristband and a mobile phone to detect smoking and high-risk triggers for smoking lapses. This allows us to automatically detect triggers associated with each user’s smoking pattern, predict when the user is most likely to experience cravings, and prevent a relapse by offering tailored, personalized intervention. The ability of the platform to deliver contextually appropriate intrevention and seamlessly integrate Just-in-Time treatment delivery into smokers’ daily lives will help make the transition from a smoker to an ex-smoker, easy and effective. What’s even better is the ability of the platform to intergrate other smoking cessation products. If the user wishes to use nicotine gum, patches, or medications while quitting, our platform is equiped to deliver medication reminders and reminders to change the patch.


Our Team

The Lumme team has been involved in a variety of highly visible projects that involve mobile sensing in the field environment, including the development of new biosensors, and clinical studies involving field deployment of sensors and analytics. The team is highly interdisciplinary, bringing together experts in computing, biomedical engineering, and smoking cessation, all with established track records of innovation. We believe that we have a strong team that can bring together innovative and well-founded ideas to innovate in how smoking cessation is done today.


Deepak Ganesan
President
Dr. Ganesan is a professor at the school of Computer Science at UMass Amherst. He has more than a decade of experience in the use of mobile health sensors including detection of behavioral targets such as cocaine use and smoking, understanding interactions between multiple behaviors through multi-modal sensing, prediction of
future behavioral context using advanced machine learning, design of novel ultra-low power behavioral sensing platforms such as computational eyeglass for visual context sensing, and incentive strategies for mobile health.


Christopher Salthouse
Chief Executive Officer
Dr. Salthouse has nearly 15 years of experience as an electrical engineer designing mixed signal circuits for a variety of biomedical applications including: cochlear implants, small animal imaging systems, point of care diagnostics, and wearable sensors.


Sherry McKee
Behavior Change Expert
Dr. McKee is a Professor in the Department of Psychiatry, Yale University School of Medicine, who has extensive experience developing effective treatments for addictive behaviors, including tobacco use, alcohol drinking, and obesity. She is a licensed clinical psychologist and is the Director of the Yale Tobacco Treatment Clinic.


Abhinav Parate
Head, Research and Development
Dr. Parate has done seminal work in detecting health behaviors such as smoking and drug use, as well as analysis methods for understanding the triggers of individual behavior. He has extensive experience with designing smartphone-based solutions that has been widely used by research groups across the country. He has worked extensively with health experts including behavioral scientists, and mental health experts.


Akshaya Shanmugam
Program Manager
Dr. Shanmugam is a recent Ph.D. graduate from UMass Amherst and is an expert in design of portable health monitoring, data analytics, and testing and validation. During her time at UMass, she has developed low cost point-of-care disease screening devices such as 3D on-sensor lensless imaging systems, microfluidic systems, and electrochemical sensors for the diagnosis of cancer, HIV, and HCV. She is also the recipient of the Hluchyj fellowship, Eugene M. Isenberg Scholar award, Special Tang award, David Wolf prize, and the Glass family product demonstration award.